CVS Health reported better-than-expected Q1 earnings with adjusted EPS of $2.57, surpassing estimates of $2.20, and sales rising 6.2% to $100.43 billion. The company saw improved operating income driven by its Health Care Benefits segment and lowered its medical benefit ratio, reflecting cost efficiencies. Despite a decline in medical membership due to exiting the individual exchange business, prescription volume grew 3.6%. CVS also raised its 2026 adjusted earnings guidance to $7.30-$7.50 per share and plans to accelerate adoption of lower-cost biosimilars to reduce drug costs further.
Aetna's latest survey shows U.S. healthcare providers' trust in payers increased to a score of 6.1 from 5.4, reflecting improved perceptions of payer reliability and communication. Providers highlight technology's role in reducing administrative task...
CVS Caremark announced a global settlement with the Federal Trade Commission (FTC) resolving all litigation related to rebate practices, pharmacy network contracting, and vertical integration. The agreement ends ongoing investigations and allows CVS ...
